The mechanism: On April 24, 2026, Acting Attorney General Todd Blanche ordered FDA-approved marijuana products and state-licensed medical marijuana into Schedule III of the Controlled Substances Act — effective April 28. It's a partial fix: adult-use weed stays Schedule I. But it flips the tax switch that matters most. IRC Section 280E denies ordinary business-expense deductions to anyone "trafficking" in a Schedule I or II substance. Move to Schedule III and 280E stops applying to the licensed medical slice of the business — turning a cannabis multi-state operator's effective tax rate from confiscatory into something resembling a normal corporation's. A DEA administrative hearing running June 29–July 15, 2026 will determine whether recreational marijuana gets swept in too. That docket, not weekly dispensary traffic, is what's actually pricing GTBIF.
Who cashes in:
- GTBIF (Green Thumb Industries) — filed DEA registration applications May 4 for its state-licensed medical operations, the fastest mover among multi-state operators. GTBIF runs medical programs in high-margin markets (Florida, Pennsylvania, Ohio) where 280E relief hits hardest. With $1.2B in 2025 revenue and
$295M in operating cash flow already, every point of effective tax rate clawed back drops straight to free cash flow — and management has been buying back stock (29M shares since September 2023), signaling confidence the DEA docket resolves in its favor. - TLRY (Tilray Brands) — included in the sector conversation but functionally exposed, not levered: Tilray is Canadian-domiciled and doesn't sell U.S. plant-touching marijuana, so 280E relief largely bypasses it. Don't mistake sector enthusiasm for company-specific catalyst exposure.